Kruger Stanley J, Niles David J, Dardzinski Bernard, Harman Amy, Jarjour Nizar N, Ruddy Marcella, Nagle Scott K, Francois Christopher J, Sorkness Ronald L, Burton Ryan M, Munoz del Rio Alejandro, Fain Sean B
Department of Medical Physics, University of Wisconsin, Madison, Wisconsin, USA.
J Magn Reson Imaging. 2014 May;39(5):1230-7. doi: 10.1002/jmri.24272. Epub 2013 Sep 4.
To investigate the utility of hyperpolarized He-3 MRI for detecting regional lung ventilated volume (VV) changes in response to exercise challenge and leukotriene inhibitor montelukast, human subjects with exercise induced bronchoconstriction (EIB) were recruited. This condition is described by airway constriction following exercise leading to reduced forced expiratory volume in 1 second (FEV1) coinciding with ventilation defects on hyperpolarized He-3 MRI.
Thirteen EIB subjects underwent spirometry and He-3 MRI at baseline, postexercise, and postrecovery at multiple visits. On one visit montelukast was given and on two visits placebo was given. Regional VV was calculated in the apical/basilar dimension, in the anterior/posterior dimension, and for the entire lung volume. The whole lung VV was used as an end-point and compared with spirometry.
Postchallenge FEV1 dropped with placebo but not with treatment, while postchallenge VV dropped more with placebo than treatment. Sources of variability for VV included region (anterior/posterior), scan, and treatment. VV correlated with FEV1/ forced vital capacity (FVC) and forced expiratory flow between 25 and 75% of FVC and showed gravitational dependence after exercise challenge.
A paradigm testing the response of ventilation to montelukast revealed both a whole-lung and regional response to exercise challenge and therapy in EIB subjects.
为了研究超极化氦 - 3磁共振成像(MRI)在检测运动激发试验和白三烯抑制剂孟鲁司特作用下局部肺通气量(VV)变化方面的效用,招募了运动诱发支气管收缩(EIB)的受试者。这种情况的特征是运动后气道收缩,导致一秒用力呼气量(FEV1)降低,同时超极化氦 - 3 MRI显示通气缺陷。
13名EIB受试者在多次就诊时于基线、运动后和恢复后接受了肺功能测定和氦 - 3 MRI检查。其中一次就诊给予孟鲁司特,两次就诊给予安慰剂。在肺尖/基底维度、前后维度以及整个肺容积中计算局部VV。将全肺VV用作终点指标,并与肺功能测定结果进行比较。
激发试验后,使用安慰剂时FEV1下降,而使用治疗药物时未下降;同时,使用安慰剂时激发试验后VV下降幅度大于使用治疗药物时。VV的变异来源包括区域(前后)、扫描和治疗。VV与FEV1/用力肺活量(FVC)以及FVC的25%至75%之间的用力呼气流量相关,并且在运动激发试验后显示出重力依赖性。
一项测试通气对孟鲁司特反应的范例揭示了EIB受试者全肺和局部对运动激发试验及治疗的反应。